Bangladesh
· Delayed Price · Currency is BDT Silva Pharmaceuticals Statistics
Total Valuation
Silva Pharmaceuticals has a market cap or net worth of BDT 1.42 billion. The enterprise value is 1.34 billion.
| Market Cap | 1.42B |
| Enterprise Value | 1.34B |
Important Dates
The next estimated earnings date is Monday, January 27, 2025.
| Earnings Date | Jan 27, 2025 |
| Ex-Dividend Date | Dec 2, 2024 |
Share Statistics
Silva Pharmaceuticals has 136.50 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 136.50M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 30.52% |
| Owned by Institutions (%) | n/a |
| Float | 66.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.59 |
| PB Ratio | 0.64 |
| P/TBV Ratio | 0.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -14.92 |
| EV / Sales | 2.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -41.26 |
Financial Position
The company has a current ratio of 11.76, with a Debt / Equity ratio of 0.02.
| Current Ratio | 11.76 |
| Quick Ratio | 4.88 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.64 |
| Interest Coverage | -14.99 |
Financial Efficiency
Return on equity (ROE) is -3.95% and return on invested capital (ROIC) is -1.95%.
| Return on Equity (ROE) | -3.95% |
| Return on Assets (ROA) | -1.87% |
| Return on Capital (ROIC) | -1.95% |
| Revenue Per Employee | 958,092 |
| Profits Per Employee | -157,204 |
| Employee Count | 596 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 0.84 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.85% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -51.85% |
| 50-Day Moving Average | 10.37 |
| 200-Day Moving Average | 14.29 |
| Relative Strength Index (RSI) | 49.35 |
| Average Volume (20 Days) | 134,396 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Silva Pharmaceuticals had revenue of BDT 547.07 million and -89.76 million in losses. Loss per share was -0.66.
| Revenue | 547.07M |
| Gross Profit | 142.80M |
| Operating Income | -72.83M |
| Pretax Income | -71.87M |
| Net Income | -89.76M |
| EBITDA | -14.01M |
| EBIT | -72.83M |
| Loss Per Share | -0.66 |
Balance Sheet
The company has 133.55 million in cash and 53.24 million in debt, giving a net cash position of 80.32 million or 0.59 per share.
| Cash & Cash Equivalents | 133.55M |
| Total Debt | 53.24M |
| Net Cash | 80.32M |
| Net Cash Per Share | 0.59 |
| Equity (Book Value) | 2.22B |
| Book Value Per Share | 16.29 |
| Working Capital | 843.14M |
Cash Flow
In the last 12 months, operating cash flow was 1.37 million and capital expenditures -33.83 million, giving a free cash flow of -32.46 million.
| Operating Cash Flow | 1.37M |
| Capital Expenditures | -33.83M |
| Free Cash Flow | -32.46M |
| FCF Per Share | -0.24 |
Margins
Gross margin is 26.10%, with operating and profit margins of -13.31% and -16.41%.
| Gross Margin | 26.10% |
| Operating Margin | -13.31% |
| Pretax Margin | -13.14% |
| Profit Margin | -16.41% |
| EBITDA Margin | -2.56% |
| EBIT Margin | -13.31% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.10, which amounts to a dividend yield of 0.96%.
| Dividend Per Share | 0.10 |
| Dividend Yield | 0.96% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 0.96% |
| Earnings Yield | -6.32% |
| FCF Yield | -2.29% |
Stock Splits
The last stock split was on November 7, 2019. It was a forward split with a ratio of 1.05.
| Last Split Date | Nov 7, 2019 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Silva Pharmaceuticals has an Altman Z-Score of 9.89.
| Altman Z-Score | 9.89 |
| Piotroski F-Score | n/a |